Compare · HSAQ vs SYK
HSAQ vs SYK
Side-by-side comparison of Health Sciences Acquisitions Corporation 2 (HSAQ) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSAQ and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 622.1x HSAQ ($201.6M).
- SYK has hit the wire 5 times in the past 4 weeks while HSAQ has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 0 for HSAQ).
- Company
- Health Sciences Acquisitions Corporation 2
- Stryker Corporation
- Price
- $13.31+25.98%
- $327.50-0.63%
- Market cap
- $201.6M
- $125.43B
- 1M return
- -
- -0.03%
- 1Y return
- -
- -10.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Health Sciences Acquisitions Corporation 2
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest HSAQ
- SEC Form 5 filed by Medtronic Plc
- SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)
- SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)
- SEC Form SC 13G filed by Health Sciences Acquisitions Corporation 2
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Health Sciences Acquisitions Corporation 2
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-1 filed by Health Sciences Acquisitions Corporation 2
- New insider Papandreou George claimed ownership of 20,000 shares (SEC Form 3)
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew